The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relevance of MIA and S-100 to monitor BRAF inhibitor (iBRAF) therapy in metastatic melanoma patients.
Miguel F. Sanmamed
No relevant relationships to disclose
Sara Fernandez-Landazuri
No relevant relationships to disclose
Eduardo Castanon
No relevant relationships to disclose
Jose Echeveste
No relevant relationships to disclose
Maria D. Lozano
No relevant relationships to disclose
Miguel A. Idoate
No relevant relationships to disclose
Jose Luis Perez-Gracia
No relevant relationships to disclose
Alvaro Gonzalez
No relevant relationships to disclose
Salvador Martin-Algarra
No relevant relationships to disclose